These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20549577)

  • 1. Polypill: lights and shadows.
    Teo KK; Liang Y
    Curr Hypertens Rep; 2010 Aug; 12(4):276-81. PubMed ID: 20549577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
    Trials; 2011 Jan; 12():3. PubMed ID: 21205325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
    Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
    Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
    Joseph P; Pais P; Dans AL; Bosch J; Xavier D; Lopez-Jaramillo P; Yusoff K; Santoso A; Talukder S; Gamra H; Yeates K; Lopez PC; Tyrwhitt J; Gao P; Teo K; Yusuf S;
    Am Heart J; 2018 Dec; 206():72-79. PubMed ID: 30342297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
    N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
    Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
    [No Abstract]   [Full Text] [Related]  

  • 14. Polypill: the evidence and the promise.
    Lonn E; Yusuf S
    Curr Opin Lipidol; 2009 Dec; 20(6):453-9. PubMed ID: 19884824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypill Variants (Quarter Pill Trials).
    Teo K; Yusuf S
    Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.